Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity.

@article{Ishizaki2006EtodolacAS,
  title={Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity.},
  author={Tetsuo Ishizaki and Kenji Katsumata and Akihiko Tsuchida and Tatehiko Wada and Yasuharu Mori and Masayuki Hisada and Hideaki Kawakita and Tatsuya Aoki},
  journal={International journal of molecular medicine},
  year={2006},
  volume={17 2},
  pages={357-62}
}
Synchronous or metachronous liver metastasis occurs in approximately 15% of colorectal cancer patients and is an important negative prognostic factor. We therefore need an effective therapy to prevent metastasis. It has become apparent that cyclooxygenase (COX)-2 plays an important role in cancer growth, invasion and metastasis and that there is potential for chemoprevention via inhibition of these processes. We injected colon 26, a colorectal cancer cell line, in CDF1 mouse spleen and, from… CONTINUE READING